|Star Scientific Announces New Anatabloc® Face Cream to Improve the Appearance of the Skin|
The Anatabloc® face cream is based upon the company's prior work with anatabine and its anatabine citrate formulation. Anatabine is an alkaloid found in Solanaceous plants, including tomatoes, peppers, eggplants, and tobacco, and has properties that improve the appearance of the skin. Anatabine citrate has been under consideration for use in the face cream since the systemic and topical safety of this natural ingredient was established. After a year of product development, which included efforts to find suitable bases for the product, consultation with several eminent dermatologists, and evaluation of pilot formulations of the cream, the company has created an effective product with promising results for the skin.
It is anticipated that initially the Anatabloc® face cream will be available on-line through the company's website www.anatabloc.com and in select dermatology practices. The Anatabloc® face cream is a natural extension of the work that the company has been involved with in connection with its Anatabloc® dietary supplement for anti-inflammatory support. Anatabloc® can be purchased in all
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the